|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Overexpression of CUG2 also induced tumor formation in xenotransplanted nude mice whereas transplantation of control cells failed to, implying that CUG2 possesses malignant tumorigenic potential.
|
31113615 |
2019 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
We propose that autophagy impairment is a potential strategy for successful VSV virotherapy of CUG2-overexpressing tumors.
|
24452380 |
2014 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Taken together, we propose that VSV treatment combined with the selective regulation of genes such as STAT1 and OASL2 will improve therapeutic outcomes for CUG2-overexpressing tumors.
|
23306614 |
2013 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Here, we describe application of multiplex real-time RT-PCR using TaqMan probes in the analysis of relative expression levels of a novel tumor-associated gene CUG2 in cell lines and tissue samples.
|
21898209 |
2011 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Taken together, these findings suggest that CUG2 is a novel tumor-associated gene that is commonly activated in various human cancers and exhibits high transforming activities; it possibly belongs to a transcription regulator family that is involved in tumor biogenesis.
|
17610844 |
2007 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Because several lines of evidence documented that Yes-Associated Protein (YAP)1 is closely associated with cancer stem cell (CSC)-like phenotypes including EMT, stemness, and drug resistance, we wondered if YAP1 is involved in CUG2-induced EMT.
|
30771899 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
We thus wonder whether CUG2 also induces stemness, a characteristic of cancer stem cells (CSCs) and further examine the molecular mechanism of this phenotype.
|
31113615 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
The suppression of β‑catenin decreased cancer stem cell (CSC)‑like phenotypes, indicating that β‑catenin is involved in CUG2‑mediated CSC‑like phenotypes.
|
30968157 |
2019 |
|
Carcinoma of lung
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of CUG2 enhanced expression levels of stemness-related factors in human lung carcinoma A549 and immortalized bronchial BEAS-2B cells.
|
31113615 |
2019 |
|
Carcinoma of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
CGK062 may thus have potential for use as a therapeutic drug against CUG2‑overexpressing lung cancer cells.
|
30968157 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
The suppression of β‑catenin decreased cancer stem cell (CSC)‑like phenotypes, indicating that β‑catenin is involved in CUG2‑mediated CSC‑like phenotypes.
|
30968157 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
We thus wonder whether CUG2 also induces stemness, a characteristic of cancer stem cells (CSCs) and further examine the molecular mechanism of this phenotype.
|
31113615 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Because several lines of evidence documented that Yes-Associated Protein (YAP)1 is closely associated with cancer stem cell (CSC)-like phenotypes including EMT, stemness, and drug resistance, we wondered if YAP1 is involved in CUG2-induced EMT.
|
30771899 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Taken together, we suggest that STAT1‑HDAC4 signaling induces malignant tumor features such as EMT and sphere formation in CUG2‑overexpressing cancer cells.
|
30226605 |
2018 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Taken together, we suggest that STAT1‑HDAC4 signaling induces malignant tumor features such as EMT and sphere formation in CUG2‑overexpressing cancer cells.
|
30226605 |
2018 |
|
Carcinoma of lung
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
EGFR expression was assessed using Western blotting, immunofluorescence and capacitance assays in A549 lung cancer and immortalized bronchial BEAS-2B cells, respectively, stably transfected with a CUG2 expression vector (A549-CUG2; BEAS-CUG2) or an empty control vector (A549-Vec; BEAS-Vec).
|
28776259 |
2017 |
|
Carcinoma of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
Suppression of autophagic genes sensitizes CUG2-overexpressing A549 human lung cancer cells to oncolytic vesicular stomatitis virus-induced apoptosis.
|
24452380 |
2014 |
|
Malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
CGK062 may thus have potential for use as a therapeutic drug against CUG2‑overexpressing lung cancer cells.
|
30968157 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Silencing YAP1 inhibited CUG2-induced cell migration and invasion.
|
30771899 |
2019 |
|
Primary malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
CGK062 may thus have potential for use as a therapeutic drug against CUG2‑overexpressing lung cancer cells.
|
30968157 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Here, we showed that STAT1 suppression decreased the expression of N‑cadherin and vimentin, biomarkers of EMT, which led to inhibition of the migration and invasion of human lung A549 cancer cells stably expressing CUG2, but did not recover E‑cadherin expression.
|
30226605 |
2018 |
|
Malignant neoplasm of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
EGFR expression was assessed using Western blotting, immunofluorescence and capacitance assays in A549 lung cancer and immortalized bronchial BEAS-2B cells, respectively, stably transfected with a CUG2 expression vector (A549-CUG2; BEAS-CUG2) or an empty control vector (A549-Vec; BEAS-Vec).
|
28776259 |
2017 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Cancer upregulated gene 2 (CUG2) enhances cell migration and invasion, but the underlying mechanism has not been revealed.
|
27974707 |
2017 |
|
Primary malignant neoplasm of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
EGFR expression was assessed using Western blotting, immunofluorescence and capacitance assays in A549 lung cancer and immortalized bronchial BEAS-2B cells, respectively, stably transfected with a CUG2 expression vector (A549-CUG2; BEAS-CUG2) or an empty control vector (A549-Vec; BEAS-Vec).
|
28776259 |
2017 |